Oncotarget

Research Papers:

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Alessandro Canella, Hector Cordero Nieves, Douglas W. Sborov, Luciano Cascione, Hanna S. Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Rizzotto, Nicola Zanesi, Volinia Stefano, Balveen Kaur, Xiaokui Mo, John C. Byrd, Yvonne A. Efebera, Craig C. Hofmeister and Flavia Pichiorri _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:31134-31150. https://doi.org/10.18632/oncotarget.5290

Metrics: PDF 1508 views  |   HTML 1622 views  |   ?  


Abstract

Alessandro Canella1,*, Hector Cordero Nieves1,*, Douglas W. Sborov2, Luciano Cascione3, Hanna S. Radomska1, Emily Smith4, Andrew Stiff1, Jessica Consiglio1,9, Enrico Caserta1, Lara Rizzotto1, Nicola Zanesi1, Volinia Stefano5, Balveen Kaur6, Xiaokui Mo7, John C. Byrd1,8, Yvonne A. Efebera8, Craig C. Hofmeister8, Flavia Pichiorri1,8

1Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

2Department of Internal Medicine, Oncology/Hematology Fellowship, The Ohio State University, Columbus, OH, USA

3Lymphoma & Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland

4Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

5Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Università degli Studi, Ferrara, Italy

6Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA

7Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA

8Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA

9Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA

*These authors have contributed equally to this work

Correspondence to:

Flavia Pichiorri, e-mail: Flavia.Pichiorri@osumc.edu

Craig C. Hofmeister, e-mail: Craig.Hofmeister@osumc.edu

Keywords: myeloma, CD44, miR-9–5p, IGF2BP3, lenalidomide

Received: July 22, 2015     Accepted: September 14, 2015     Published: September 25, 2015

ABSTRACT

Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising novel chemotherapeutics undergoing evaluation in clinical trials for the potential treatment of patients with MM. Although in preclinical studies HDACi's have proven anti-myeloma activity, but in the clinic single-agent HDACi treatments have been limited due to low tolerability. Improved clinical outcomes were reported only when HDACi's were combined with other drugs. Here, we show that a novel pan-HDACi AR-42 downregulates CD44, a glycoprotein that has been associated with lenalidomide and dexamethasone resistance in myeloma both in vitro and in vivo. We also show that this CD44 downregulation is in part mediated by miR-9–5p, targeting insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), which directly binds to CD44 mRNA and increases its stability. Importantly, we also demonstrate that AR-42 enhances anti-myeloma activity of lenalidomide in primary MM cells isolated from lenalidomide resistant patients and in in vivo MM mouse model. Thus, our findings shed light on potential novel combinatorial therapeutic approaches modulating CD44 expression, which may help overcome lenalidomide resistance in myeloma patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5290